Single-center, Open-label, Randomized, Two-treatment, Single-dose, Crossover Study in Healthy Subjects to Investigate the Biocomparison of the Adult and Pediatric Formulation of Macitentan

Trial Profile

Single-center, Open-label, Randomized, Two-treatment, Single-dose, Crossover Study in Healthy Subjects to Investigate the Biocomparison of the Adult and Pediatric Formulation of Macitentan

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Macitentan (Primary)
  • Indications Eisenmenger complex; Glioblastoma; Pulmonary arterial hypertension
  • Focus Pharmacokinetics
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 07 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 22 Sep 2015 Status changed from not yet recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 14 Aug 2015 According to the ClinicalTrials.gov record, planned initiation date changed from 1 Jul 2015 to 1 Aug 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top